ArtNr |
HY-10442-1mg |
Hersteller |
MedChem Express
|
CAS-Nr. |
102052-95-9 |
Menge |
1 mg |
Quantity options |
100 mg
10mg
1 ea
1 mg
5 mg
|
Specific against |
other |
Purity |
99.97 |
Citations |
Cancers (Basel). 2022 Jul 23;14(15):3600. Cell Death Dis. 2020 Oct 23;11(10):906. Cell Rep. 2023 May 23;42(6):112550. Cell Reprogram. 2017 Dec;19(6):363-371. Cells Tissues Organs. 2021 Jan 18;1-9. Int Immunopharmacol. 2022 Feb 19;106:108612. J Am Soc Nephrol. 2016 Jul;27(7):2021-34. J Immunother Cancer. 2019 Nov 14;7(1):300. J Mol Cell Cardiol. 2019 Oct;135:119-133. Lab Invest. 2021 Mar 10. Nat Commun. 2021 Feb 23;12(1):1237. Patent. US20180263995A1. Research Square Preprint. 2020 May. Research Square Print. September 13th, 2022. Apoptosis. 2020 Oct;25(9-10):697-714. Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067. bioRxiv. 2023 Apr 21. bioRxiv. 2024 May 18. Cell Signal. 2023 Dec 30:115:111029. Exp Mol Pathol. 2020 Feb;112:104344. J Pharmacol Exp Ther. 2019 Sep;370(3):490-503. Nat Commun. 2022 Jan 10;13(1):12. Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May. [1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743. [2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46. [3]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43. [4]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302. [5]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34. [6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146. [7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. |
Smiles |
O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N |
Alias |
DZNep; 3-Deazaneplanocin |
Lieferbar |
|
Product Description |
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7]. |
StorageTemperature |
-20°C, 3 years; 4°C, 2 years (Powder) |
Shipping |
Room Temperature |
MolecularWeight |
262.26 |
Clinical Information |
No Development Reported |
Manufacturers Research Area |
Cancer; Infection |
Solubility |
H2O : 100 mg/mL (ultrasonic) |
Target |
Histone Methyltransferase; Orthopoxvirus |
Manufacturers Target |
Histone Methyltransferase; Orthopoxvirus |
Isoform |
EZH2 |
Manufacturers Pathway |
Anti-infection; Epigenetics |
Manufacturers Product type |
Reference compound |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.